(Q40391910)

20 September 2017

1 reference

title

Ceftibuten. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy (English)

1 reference

20 September 2017

1 reference

L R Wiseman

1

1 reference

20 September 2017

J A Balfour

series ordinal

2

1 reference

20 September 2017

publication date

1 May 1994

1 reference

20 September 2017

1 reference

20 September 2017

volume

47

1 reference

20 September 2017

issue

5

1 reference

20 September 2017

page(s)

784-808

1 reference

Efficacy of ceftibuten for acute otitis media caused by Hemophilus influenzae: an animal study.

20 September 2017

cites work

1 reference

12 December 2020

Ceftibuten: a review of antimicrobial activity, spectrum and other microbiologic features.

1 reference

12 December 2020

In vitro susceptibility of Helicobacter pylori to the new oral cephalosporins cefpodoxime, ceftibuten and cefixime.

1 reference

12 December 2020

In vitro activity of ceftibuten against Haemophilus influenzae and Branhamella catarhallis.

1 reference

12 December 2020

Third-Generation Cephalosporins in the Treatment of Acute Pneumococcal Otitis Media: An Animal Study

1 reference

12 December 2020

Pharmacokinetics and tissue penetration of ceftibuten

1 reference

12 December 2020

Clinical examination of ceftibuten in acute bronchitis

1 reference

12 December 2020

Ability of ceftibuten to induce the class-I beta-lactamases of Enterobacter cloacae, Serratia marcescens, and Enterobacter aerogenes.

1 reference

12 December 2020

Comparative in vitro activity of ceftibuten (Sch 39720) against bacterial enteropathogens

1 reference

12 December 2020

Comparison of the efficacy and safety of ceftibuten and cefaclor in the treatment of pneumonia and bronchiectasis

1 reference

12 December 2020

[Clinical studies on ceftibuten in the urinary field infection].

1 reference

12 December 2020

Clinical experience with ceftibuten in complicated urinary tract infections

1 reference

12 December 2020

In vitro activities of 15 oral beta-lactams against Klebsiella pneumoniae harboring new extended-spectrum beta-lactamases

1 reference

12 December 2020

In vitro activities and targets of three cephem antibiotics against Haemophilus influenzae

1 reference

12 December 2020

Ceftibuten versus cefaclor for the treatment of bronchitis

1 reference

12 December 2020

Postantibiotic effect of ceftibuten on respiratory pathogens

1 reference

12 December 2020

Ceftibuten and bactericidal kinetics. Comparative in vitro activity against Enterobacteriaceae producing extended spectrum beta-lactamases

1 reference

12 December 2020

Single-dose pharmacokinetics of ceftibuten (SCH 39720) in infants and children

1 reference

12 December 2020

Ceftibuten: minimal inhibitory concentrations, postantibiotic effect and beta-lactamase stability--a rationale for dosing programs

1 reference

12 December 2020

The Efficacy and Safety of Once-Daily Ceftibuten Compared with Co-amoxiclav in the Treatment of Acute Bacterial Sinusitis

1 reference

12 December 2020

Comparative in-vitro activity of the penem FCE 22101 against recent European blood culture isolates

1 reference

12 December 2020

The pharmacokinetics of ceftibuten in humans

1 reference

12 December 2020

[Therapeutic efficacy of ceftibuten in chronic respiratory tract infections]

1 reference

12 December 2020

Pharmacokinetics of new oral cephalosporins, including a new carbacephem

1 reference

12 December 2020

The in-vitro activity of ceftibuten against 475 clinical isolates of gram-negative bacilli, compared with cefuroxime and cefadroxil

1 reference

12 December 2020

Phase I clinical studies of 7432-S: effect of 7432-S on platelet aggregation and blood coagulation

1 reference

12 December 2020

Comparative antimicrobial spectrum and activity of ceftibuten against clinical isolates from West Germany

1 reference

12 December 2020

[Comparative antibacterial activity of ceftibuten (SH 39 720) against 150 K. pneumoniae strains producing different beta-lactamases]

1 reference

12 December 2020

Antibacterial Activity of Ceftibuten, a New Oral Third Generation Cephalosporin

1 reference

12 December 2020

In vitro evaluation of ceftibuten (7432-S, SCH 39720), a novel orally administered cephalosporin

1 reference

12 December 2020

Antimicrobial activity, spectrum, and recommendations for disk diffusion susceptibility testing of ceftibuten (7432-S; SCH 39720), a new orally administered cephalosporin

1 reference

12 December 2020

Phase I Clinical Studies of 7432-S, a New Oral Cephalosporin: Safety and Pharmacokinetics

1 reference

12 December 2020

Comparative in vitro activities of several new fluoroquinolones and beta-lactam antimicrobial agents against community isolates of Streptococcus pneumoniae

1 reference

12 December 2020

Kinetics of filamentation of Escherichia coli induced by different sub-MICs of ceftibuten at different times.

1 reference

12 December 2020

Multinational multicenter controlled trial comparing ceftibuten with cefaclor for the treatment of acute otitis media. Members of the Ceftibuten Otitis Media International Study Group.

1 reference

12 December 2020

[Clinical studies of ceftibuten in the field of urology]

1 reference

12 December 2020

Ceftibuten--in-vitro activity against respiratory pathogens, beta-lactamase stability and mechanism of action.

1 reference

12 December 2020

Activities of beta-lactam antibiotics against Escherichia coli strains producing extended-spectrum beta-lactamases

1 reference

12 December 2020

Microbiologic profile of ceftibuten, a new oral cephalosporin

1 reference

12 December 2020

Treatment of acute uncomplicated urinary tract infection with ceftibuten

1 reference

12 December 2020

Effect of ceftibuten on the normal intestinal microflora.

1 reference

12 December 2020

Ceftibuten: a new orally absorbed cephalosporin. In vitro activity against strains from the United Kingdom

1 reference

12 December 2020

Pharmacokinetics of ceftibuten-cis and its trans metabolite in healthy volunteers and in patients with chronic renal insufficiency

1 reference

12 December 2020

Ceftibuten (7432-S, SCH 39720): comparative antimicrobial activity against 4735 clinical isolates, beta-lactamase stability and broth microdilution quality control guidelines

1 reference

12 December 2020

In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to six new oral cephalosporins

1 reference

12 December 2020

Interpretive criteria and quality control limits for ceftibuten disk susceptibility tests. Collaborative Antimicrobial Susceptibility Testing Group

1 reference

12 December 2020

Susceptibilities of beta-lactamase-producing and -nonproducing ampicillin-resistant strains of Haemophilus influenzae to ceftibuten, cefaclor, cefuroxime, cefixime, cefotaxime, and amoxicillin-clavulanic acid

1 reference

12 December 2020

In-vitro activity of FCE 22101 against respiratory tract pathogens with reference to production of beta-lactamases.

1 reference

12 December 2020

Ceftibuten and trimethoprim-sulfamethoxazole for treatment of Shigella and enteroinvasive Escherichia coli disease

1 reference

12 December 2020

Comparative antimicrobial activity of ceftibuten against multiply-resistant microorganisms from Belgium

1 reference

12 December 2020

Sub-minimum inhibitory concentrations of ceftibuten reduce adherence of Escherichia coli to human cells and induces formation of long filaments.

1 reference

12 December 2020

Randomized comparative study of ceftibuten versus cefaclor in the treatment of acute lower respiratory tract infections

1 reference

12 December 2020

The in vitro effects of ceftibuten on the host defense mechanism.

1 reference

12 December 2020

10.2165/00003495-199447050-00006

Identifiers

DOI

1 reference

Dimensions Publication ID

20 September 2017

1052361372

0 references

1 reference